Obesity is Not Associated With Need for Skin Grafting After Hidradenitis Excision

Abstract

Introduction

Hidradenitis suppurativa (HS) is a chronic, debilitating disease associated with inflammation, recurrent abscesses, and fistulae of skin containing apocrine sweat glands. We hypothesize that the need for skin grafting after vacuum-assisted closure was decreased with increasing body mass index (BMI).

Methods

Seventy-one consecutive patients with excisions for HS were retrospectively evaluated for demographic data, number of excisions, the total area of excised skin, need for skin grafting, and BMI. Patients were stratified for BMI and underwent logistic regression to compare all other variables.

Results

Average for BMI was 30.8 ± 7.72, age was 36.89 ±13.52, area excised was 743 cm² ± 774 cm², mean operating room trips were 2.62 ± 1.59, and skin grafting was 0.52 ± 0.55. Patients were 60% male. Forty out of 71 patients were obese. There was no correlation between age, BMI, sex, thenumber of excisions, amount of skin excised, or need for a skin graft. There was a statistically significant relationship between the amount of skin excised and the need for skin grafting (P = .006).

Conclusions

The amount of skin affected by HS appears to be independent of patient BMI. The need for skin grafting is solely dependent upon the amount of tissue excised.

Applicability of research to practice

This knowledge will help preoperative planning for all patients with HS, regardless of BMI.

Keywords

hidradenitis suppurativa skin grafting obesity

Get full access to this article

View all access options for this article.

References

Grewal

NS.

Wan

DC.

Roostaeian

Rubayi

. Marjolin ulcer in hidradenitis suppurativa: case reports. Ann Plast Surg. 2010;64(3):315-317.doi:10.1097/SAP.0b013e3181a7302a

Alikhan

Lynch

PJ.

Eisen

. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539-561.doi:10.1016/j.jaad.2008.11.911

Jemec

GBE

. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164.doi:10.1056/NEJMcp1014163

Sartorius

Emtestam

Jemec

GBE.

Lapins

. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831-839.doi:10.1111/j.1365-2133.2009.09198.x

Manolitsas

Biankin

Jaworski

Wain

. Vulval squamous cell carcinoma arising in chronic hidradenitis suppurativa. Gynecol Oncol. 1999;75(2):285-288.doi:10.1006/gyno.1999.5547

Tzellos

Zouboulis

. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther. 2020;10(1):63-71.doi:10.1007/s13555-020-00354-2

Yazdanyar

Jemec

GBE

. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis. 2011;24(2):118-123.doi:10.1097/QCO.0b013e3283428d07

Frew

JW.

Hawkes

JE.

Krueger

JG.

Topical

KJG

. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646doi:10.1177/2040622319830646

Büyükaşik

Hasdemir

AO.

Kahramansoy

Çöl

Erkol

. Surgical approach to extensive hidradenitis suppurativa. Dermatol Surg. 2011;37(6):835-842.doi:10.1111/j.1524-4725.2011.01961..x

10.

Chen

Friedman

. Management of regional hidradenitis suppurativa with vacuum-assisted closure and split thickness skin grafts. Ann Plast Surg. 2011;67(4):397-401.doi:10.1097/SAP.0b013e3181f77bd6

11.

Ellis

. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg. 2012;38(4):517-536.doi:10.1111/j.1524-4725.2011.02186.x

12.

Sharma

Schwarts

RA.

Swan

. Marjolin’s warty ulcer. J SurgOncol. 2011;103(2):193-195.

13.

Revuz

JE.

Canoui-Poitrine

Wolkenstein

et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596-601.doi:10.1016/j.jaad.2008.06.020

14.

Vazquez

BG.

Alikhan

Weaver

AL.

Wetter

DA.

Davis

. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97-103.doi:10.1038/jid.2012.255

15.

Bettoli

Naldi

Cazzaniga

et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa–acne inversa: evidence from the National Italian registry. Br J Dermatol. 2016;174(1):195-197.doi:10.1111/bjd.13864

16.

Kromann

CB.

Ibler

KS.

Kristiansen

VB.

Jemec

GBE

. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94(5):553-557.doi:10.2340/00015555-1800

17.

Dessinioti

Katsambas

Antoniou

. Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol. 2014;32(3):397-408.doi:10.1016/j.clindermatol.2013.11.006

18.

Gold

DA.

Reeder

VJ.

Mahan

MG.

Hamzavi

. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699-703.doi:10.1016/j.jaad.2013.11.014

19.

Janse

IC.

Koldijk

MJ.

Spekhorst

et al. Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(1):106-113.doi:10.1097/MIB.0000000000000579

20.

Kohorst

JJ.

Kimball

AB.

Davis

MDP

. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27-S35.doi:10.1016/j.jaad.2015.07.055

21.

Shalom

Freud

Harman-Boehm

Polishchuk

Cohen

. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173(2):464-470.doi:10.1111/bjd.13777

22.

Shlyankevich

Chen

AJ.

Kim

GE.

Kimball

. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014;71(6):1144-1150.doi:10.1016/j.jaad.2014.09.012

23.

Vinding

GR.

Miller

IM.

Zarchi

et al. The prevalence of inverse recurrent Suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170(4):884-889.doi:10.1111/bjd.12787

24.

Kromann

CB.

Deckers

IE.

Esmann

et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171(4):819-824.doi:10.1111/bjd.13090

25.

Schmitt

JV.

Bombonatto

Martin

Miot

. Risk factors for hidradenitis suppurativa: a pilot study. An Bras Dermatol. 2012;87(6):936-938.doi:10.1590/S0365-05962012000600024

26.

Nazary

van der Zee

HH.

Prens

EP.

Folkerts

Boer

et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. Eur J Pharmacol. 2011;672(1-3):1-8.doi:10.1016/j.ejphar.2011.08.047

27.

Miller

IM.

Ellervik

Vinding

et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150(12):1273-1280.doi:10.1001/jamadermatol.2014.1165

28.

Thomas

CL.

Gordon

KD.

Mortimer

. Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention. Clin Exp Dermatol. 2014;39(3):315-318.doi:10.1111/ced.12269

29.

Chen

YE.

Gerstle

Verma

et al. Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. Plast Reconstr Surg. 2014;133(3):370e-377.doi:10.1097/PRS.0000000000000080